BMS-986403 / BMS - LARVOL DELTA

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - P1 | N=5 | Terminated | Sponsor: Bristol-Myers Squibb | N=65 ➔ 5 | Trial completion date: Mar 2025 ➔ May 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Mar 2025 ➔ May 2023; Business objectives have changed.

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - P1 | N=65 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2029 ➔ Mar 2025 | Trial primary completion date: Jan 2029 ➔ Mar 2025

Enrollment closed • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - P1 | N=65 | Recruiting | Sponsor: Bristol-Myers Squibb | N=40 ➔ 65 | Trial completion date: Jun 2027 ➔ Jan 2029 | Trial primary completion date: Jun 2027 ➔ Jan 2029

Enrollment change • Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Bristol-Myers Squibb | Initiation date: Jun 2022 ➔ Sep 2022

Trial initiation date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma

A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting | N=65 ➔ 40 | Trial completion date: Mar 2027 ➔ Jun 2027 | Initiation date: Feb 2022 ➔ Jun 2022 | Trial primary completion date: Mar 2027 ➔ Jun 2027

Enrollment change • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma